EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin

Emilia Cercenado iD, Mercedes Marín, Manuel Iglesias, Laura Jiménez, Marta Pérez-Abeledo, Juan Carlos Sanz

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Emilia Cercenado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General, Universitario Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Fluoroquinolones, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Investigator Initiated Trial (IIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Delafloxacin is a dual-targeting fluoroquinolone against topoisomerase IV and DNA gyrase that could decrease resistance selection by diminishing the likelihood of multiple mutational events in both enzymes.

Objectives

To determine the activity of delafloxacin against invasive Streptococcus pneumoniae isolates resistant to levofloxacin (LEV-R), compare delafloxacin MICs for LEV-R isolates with those of susceptible strains, and analyse mutations in QRDRs.

Methods

A total of 130 S. pneumoniae isolates (2014–20) were studied. The isolates were distributed according to levofloxacin MICs: high-level LEV-R (n = 46; MIC > 32 mg/L), low-level LEV-R (n = 36; MIC range 3–12 mg/L) and susceptible (LEV-S; n = 48; MIC ≤2 mg/L). We considered delafloxacin-resistant to be MIC ≥ 0.12 mg/L (EUCAST epidemiological cut-off). MICs were determined by gradient diffusion (control strain S. pneumoniae ATCC 49619). All isolates were subjected to PCR and sequencing of parC, parE, gyrA and gyrB genes.

Results

All LEV-S isolates showed delafloxacin MICs of ≤0.008 mg/L, and did not show mutations in QRDRs. Isolates with levofloxacin MICs of 3–12 mg/L showed delafloxacin MICs of <0.12 mg/L, with 3 (8.3%) presenting mutations in gyrA, and 11 (30.6%) in parC previously related to resistance. Isolates with levofloxacin MICs of >32 mg/L showed two to four mutations in QRDRs and 11 (24%) were delafloxacin resistant, presenting at least two mutations in gyrAS81F/L/V + parCS79F; four accumulated three mutations, and two showed four mutations in QRDRs.

Conclusions

Among LEV-R pneumococci, 71 (87%) were susceptible to delafloxacin, indicating that it maintains its activity despite the presence of mutations in gyrA + parC that lead to high-level resistance to levofloxacin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcus pneumoniaeFluoroquinolonesAnti-Bacterial AgentsDrug Resistance, BacterialMicrobial Sensitivity TestsHumansPneumococcal InfectionsDNA GyraseDNA Topoisomerase IVLevofloxacinMutation

Substanzen

FluoroquinolonesAnti-Bacterial AgentsdelafloxacinDNA GyraseDNA Topoisomerase IVLevofloxacin

Autor:innen und Institutionen

  • Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General, Universitario Gregorio Marañón, Madrid, Spain.
  • Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, Spain.
  • Medicine Department, School of Medicine, Universidad Complutense, Madrid, Spain.
  • CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain.
  • Medical Department, Menarini, Madrid, Spain.
  • Unidad de Microbiología Clínica, Laboratorio Regional de Salud Pública de la Comunidad de Madrid, Madrid, Spain.

ORCID-Profile: Emilia Cercenado

Förderung

  • the Investigator Initiated Trial (IIT)

Zitieren

APA

Cercenado, E., Marín, M., Iglesias, M., Jiménez, L., Pérez-Abeledo, M., & Sanz, J. C. (2025). Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf308

Vancouver

Cercenado E, Marín M, Iglesias M, Jiménez L, Pérez-Abeledo M, Sanz JC. Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf308

BibTeX
@article{Cercenado2025,
  author = {Cercenado, Emilia and Marín, Mercedes and Iglesias, Manuel and Jiménez, Laura and Pérez-Abeledo, Marta and Sanz, Juan Carlos},
  title = {Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf308}
}
Kostenlos starten →